An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator's Choice of Therapy in Adult Participants With Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
Latest Information Update: 16 Jan 2026
At a glance
- Drugs Prifetrastat (Primary) ; Everolimus; Exemestane; Fulvestrant
- Indications HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 15 Aug 2025 Planned primary completion date changed from 2 Nov 2027 to 22 Jul 2027.
- 15 Aug 2025 Status changed from not yet recruiting to recruiting.
- 25 Jul 2025 New trial record